help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mancini, L.
Right arrow Articles by Perretti, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mancini, L.
Right arrow Articles by Perretti, M.
(American Journal of Pathology. 2007;170:1018-1027.)
© 2007 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2007.060830

Calcitonin and Prednisolone Display Antagonistic Actions on Bone and Have Synergistic Effects in Experimental Arthritis

Lucia Mancini, Mark J. Paul-Clark, Guglielmo Rosignoli, Robert Hannon, Jo E. Martin, Ian Macintyre and Mauro Perretti

From The William Harvey Research Institute, London, United Kingdom

We tested here the hypothesis that calcitonin and glucocorticoids, known to modulate bone metabolism, could have opposite actions on bone cells regulating expression of cytokine receptor activator of nuclear factor-{kappa}B ligand (RANKL) and osteoprotegerin (OPG). In the U2OS osteosarcoma cell line, calcitonin (10–11 to 10–9 mol/L) reduced RANKL and augmented OPG both at the mRNA and protein levels. Cell incubation with prednisolone (10–8 to 10–6 mol/L), the glucocorticoid chosen for this study, produced opposite results. These molecular studies prompted more functional analyses whereby osteoclast bone resorptive activity was determined. Calcitonin (10–10 mol/L) abrogated the stimulating effect of 10 ng/ml RANKL or 10–9 mol/L prednisolone; similar results were obtained with OPG. Assessment of calcitonin and prednisolone effects in an in vivo model of rheumatoid arthritis revealed partially surprising results. In fact, calcitonin not only preserved bone morphology (as assessed on day 18) in rats subjected to arthritis and treated with prednisolone (0.8 to 4 mg/kg daily from day 13) but also synergized with the steroid to elicit its antiarthritic effects. These results suggest that calcitonin could be used as a novel cotreatment to augment efficacy and reduce side effects associated with the prolonged use of steroids.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
B. R. Becklund, D. W. Hansen Jr., and H. F. DeLuca
Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin
PNAS, March 31, 2009; 106(13): 5276 - 5281.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society for Investigative Pathology.